Brief: Daré Bioscience Announces Interim Analysis Of Phase 2B RESPOND Study Of Sildenafil Cream, 3.6%

Dare Bioscience

29/08/2022 13:10

Aug 29 (Reuters) - Dare Bioscience Inc  DARE.O :
    * DARÉ BIOSCIENCE ANNOUNCES INTERIM ANALYSIS OF PHASE 2B
RESPOND
STUDY OF SILDENAFIL CREAM, 3.6% IN WOMEN WITH FEMALE SEXUAL
AROUSAL DISORDER
    * DARE BIOSCIENCE INC- STUDY ENROLLMENT EXPECTED TO COMPLETE
IN
4Q-2022 WITH APPROXIMATELY 150 SUBJECTS
    * DARE BIOSCIENCE INC- TOPLINE DATA OF PHASE 2B RESPOND
STUDY
TARGETED FOR 2Q-2023

Source text for Eikon:  ID:nGNX30QDf1 
Further company coverage:  DARE.O 

 ((Reuters.Briefs@thomsonreuters.com;;))